
Howard S. Hochster, MD, discusses the role of TAS-102 in patients with gastric/gastroesophageal junction or colorectal cancer in comparison to fluorouracil.

Your AI-Trained Oncology Knowledge Connection!


Howard S. Hochster, MD, discusses the role of TAS-102 in patients with gastric/gastroesophageal junction or colorectal cancer in comparison to fluorouracil.

Howard S. Hochster, MD, professor of Medical Oncology, and Yale Cancer Center Associate Director (for Clinical Sciences), discusses steps that can be taken to tackle some of the challenges that remain in the field of pancreatic cancer.

Published: August 15th 2019 | Updated:

Published: November 16th 2016 | Updated: